{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li Z"],"funding":["NIAID NIH HHS","National Cancer Institute","NCI NIH HHS","NINDS NIH HHS","National Institutes of Health","California Institute for Regenerative Medicine","NIAMS NIH HHS","Leukemia and Lymphoma Society"],"pagination":["624-641.e23"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11442011"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["187(3)"],"pubmed_abstract":["The therapeutic potential for human type 2 innate lymphoid cells (ILC2s) has been underexplored. Although not observed in mouse ILC2s, we found that human ILC2s secrete granzyme B (GZMB) and directly lyse tumor cells by inducing pyroptosis and/or apoptosis, which is governed by a DNAM-1-CD112/CD155 interaction that inactivates the negative regulator FOXO1. Over time, the high surface density expression of CD155 in acute myeloid leukemia cells impairs the expression of DNAM-1 and GZMB, thus allowing for immune evasion. We describe a reliable platform capable of up to 2,000-fold expansion of human ILC2s within 4 weeks, whose molecular and cellular ILC2 profiles were validated by single-cell RNA sequencing. In both leukemia and solid tumor models, exogenously administered expanded human ILC2s"],"journal":["Cell"],"pubmed_title":["Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death."],"pmcid":["PMC11442011"],"funding_grant_id":["TRAN1-14716","R01 CA266457","CA264512","P01 CA163205","CA266457","R21 CA223400","AI129582","R01 CA247550","R01 AR070116","CA265095","CA210087","NS106170","R01 NS106170","P30 CA033572","DISC2-14190","R01 CA265095","P30CA033572","R35 CA210087","CA223400","CA163205","CA247550","U19 CA264512","TRAN1-14003","1364–19","R01 AI129582"],"pubmed_authors":["Artis D","Ma R","Li Z","Guo J","Zhang J","Liu N","Cao S","Marcucci G","Yu J","Caligiuri MA","Tang H","Shah Z"],"additional_accession":[]},"is_claimable":false,"name":"Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death.","description":"The therapeutic potential for human type 2 innate lymphoid cells (ILC2s) has been underexplored. Although not observed in mouse ILC2s, we found that human ILC2s secrete granzyme B (GZMB) and directly lyse tumor cells by inducing pyroptosis and/or apoptosis, which is governed by a DNAM-1-CD112/CD155 interaction that inactivates the negative regulator FOXO1. Over time, the high surface density expression of CD155 in acute myeloid leukemia cells impairs the expression of DNAM-1 and GZMB, thus allowing for immune evasion. We describe a reliable platform capable of up to 2,000-fold expansion of human ILC2s within 4 weeks, whose molecular and cellular ILC2 profiles were validated by single-cell RNA sequencing. In both leukemia and solid tumor models, exogenously administered expanded human ILC2s","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-06-01T18:12:06.874Z","creation":"2025-04-05T19:19:18.416Z"},"accession":"S-EPMC11442011","cross_references":{"pubmed":["38211590"],"doi":["10.1016/j.cell.2023.12.015"]}}